7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Evaluation of a 7-Day Therapeutic Trial Dose of Commercial Sucraid® (Sacrosidase) Oral Solution for Alleviating Congenital Sucrase-Isomaltase Deficiency (CSID) Symptoms in Pediatric Subjects With Low, Moderate, and Normal Sucrase Levels

This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).

Study Overview

• Status: Terminated
• Conditions: Congenital Sucrase-Isomaltase Deficiency; CSID; Sucrase Isomaltase Deficiency
• Intervention / Treatment: Biological: Sucraid (sacrosidase) Oral Solution 8500 IU/mL

Detailed Description

This phase 4 study will evaluate the response to Sucraid® in pediatric subjects aged 6 months to 17 years old with low (< 25 µM/min/gram protein), moderate (25-35 µM/min/gram protein), and normal (> 55 µM/min/gram protein) sucrase activities. Subjects with a sucrase level via disaccharidase assay from an EGD within 1 year of informed consent/assent, a normal histological interpretation, and at the discretion of the investigator, at least one symptom of carbohydrate maldigestion (CMS) of postprandial diarrhea, abdominal pain, gas/bloating, or defecation urgency at least 3 times per week for the past 3 months or more will be eligible for study participation. This study will also explore the relationship between three groups of sucrase levels from the EGD disaccharidase assay and the genetic test. This study will consist of a Screening Visit, Run-in Period, Baseline Visit, Treatment Period, and Follow-up Visit.

• Study Type: Interventional
• Enrollment (Actual): 312
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90027
      • Children's Hospital Los Angeles
    • Oakland, California, United States, 94609
      • UCSF Benioff Children's Hospital Oakland
  • Florida
    • Coral Gables, Florida, United States, 33146
      • Kidz Medical
    • Orlando, Florida, United States, 32806
      • Orlando Health
  • Georgia
    • Atlanta, Georgia, United States, 30329
      • Children's Healthcare of Atlanta
    • Atlanta, Georgia, United States, 30342
      • Center for Digestive Health Care, LLC
  • Maryland
    • Baltimore, Maryland, United States, 21205
      • Johns Hopkins University
    • Baltimore, Maryland, United States, 21201
      • University of Maryland Baltimore
  • Mississippi
    • Flowood, Mississippi, United States, 39232
      • GI Associates
    • Flowood, Mississippi, United States, 39232
      • Happy Tummies
  • Missouri
    • Kansas City, Missouri, United States, 64108
      • Children's Mercy Hospital
  • New Jersey
    • Morristown, New Jersey, United States, 07960
      • Atlantic Health System
  • New York
    • Buffalo, New York, United States, 14225
      • WNY Pediatric Gastroenterology
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • University Hospitals Cleveland Medical Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Measurable Outcomes Research
  • South Carolina
    • Greenville, South Carolina, United States, 29615
      • Prisma Health
  • Tennessee
    • Knoxville, Tennessee, United States, 32963
      • GI For Kids, PLLC
  • Texas
    • El Paso, Texas, United States, 79902
      • Newco 3A Research,LLC DBA 3A Research
    • El Paso, Texas, United States, 79925
      • Pediatric GI of El Paso, LLC
    • Houston, Texas, United States, 77030
      • McGovern Medical School of UT Health

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 6 months to 17 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects with documented disaccharidase assay levels of lactase, sucrase, maltase, and palatinase via EGD disaccharidase assay (DA) performed no more than 1 year prior to enrollment with normal histological interpretation. Eligible subjects will be enrolled into the following study groups based on their documented sucrase level.
• DA Sucrase < 25 (n=500)
• DA Sucrase 25-35 (n=500)
• DA Sucrase >55 (n=100)
• At the discretion of the investigator, subject is suspected of CSID and has at least one symptom of diarrhea, abdominal pain, gas/bloating, nausea, or borborygmi at least 3x per week for the past 3 months or more.
• Subject or parent/guardian must provide informed consent/assent prior to any study procedures being performed.
• Subject is a U.S. resident.
• Subject is male or female, ages 6 months to 17 years old.
• Subject/parent or guardian is willing and able to complete necessary study procedures including following study instructions, completing electronic questionnaires via a personal mobile device, attending study visits and, in the Investigator's judgment, is sufficiently stable to participate in the study.
• Subject/ parent or guardian must be able to read or understand the English language.
• Subject or parent/guardian must have their own Android or Apple device for BYOD.

Exclusion Criteria:

• Females who are lactating or pregnant.
• Subjects with allergy to sucrose, yeast, papain, or glycerol.
• Subjects with causes of abdominal pain or altered bowel habits other than CSID such as inflammatory bowel disease, celiac disease, eosinophilic gastrointestinal disorder, pancreatitis, or gastrointestinal bleeding.
• Subjects with a history of diabetes mellitus.
• Subjects with a recent febrile illness (5 days prior to study).
• Subjects that do not have the mental capacity to understand the study requirements and are unable to comply.
• Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.
• Subject has previously used Sucraid®.
• Subject has uncontrolled systematic disease.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single Arm Open Labeled Commercial Sucraid; All subjects will complete a 7-day treatment period of open-labeled FDA approved commercial Sucraid.	Biological: Sucraid (sacrosidase) Oral Solution 8500 IU/mL; Sucraid is a pale yellow to colorless, clear solution of glycerol, water, and citric acid, with a pleasant, sweet taste. Each milliliter of Sucraid contains 8,500 IU of the enzyme sacrosidase, the active ingredient.; Other Names: Sacrosidase; Sucraid

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effects of Sucraid® treatment on gastrointestinal symptoms in subjects with low, moderate, and normal disaccharidase assay sucrase levels from an esophagogastroduodenoscopy (EGD).	The primary endpoint will be the difference observed between the average symptom severity/frequency score during the 7-day treatment period and the 7-day run-in period as determined by the Daily Symptom Questionnaire using a scale from 0 to 5 or more.	Post 7-day run-in period plus 7-day treatment period.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, moderate, and normal).	The number and percentage of subjects with genetic CSID mutations will also be examined in low, moderate, and normal sucrase study group.	Up to 2 years

Collaborators and Investigators

• Sponsor: QOL Medical, LLC
• Investigators: Principal Investigator: Weng Tao, M.D., Ph. D, QOL Medical

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2022
• Primary Completion (Actual): September 18, 2024
• Study Completion (Actual): September 18, 2024

Study Registration Dates

• First Submitted: June 28, 2022
• First Submitted That Met QC Criteria: July 27, 2022
• First Posted (Actual): July 29, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 17, 2025
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: www.tummyachestudy.com
• Additional Relevant MeSH Terms: Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases; Carbohydrate Metabolism, Inborn Errors
• Other Study ID Numbers: SSDXP-13

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No